Comparison of two analytical platforms for quantification of neuroglial biomarkers in blood samples: a single molecule array and an electrochemiluminescence assay.

Julia Aulin, Asma Al-Grety, Karl Sjölin, Ida Erngren, Anders Larsson, Anders Svenningsson, Kim Kultima, Joachim Burman

Abstract readComparative Study

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Nanomaterial-enhanced biosensors for traumatic brain injury biomarker detection: a review of analytical performance, machine learning integration, clinical validation, and point-of-care translation.Frontiers in neurology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Julia Aulin *Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.

Asma Al-Grety *Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Karl SjölinDepartment of Medical Sciences, Translational Neurology, Uppsala University, S-751 85, Uppsala, Sweden.

Ida ErngrenDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Anders LarssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Anders SvenningssonDepartment of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden.

Kim Kultima *Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Joachim Burman *Department of Medical Sciences, Translational Neurology, Uppsala University, S-751 85, Uppsala, Sweden. joachim.burman@uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in ultrasensitive immunoassays have enabled reliable quantification of neuroglial biomarkers in blood, providing valuable insights into neurological disorders. However, cross-platform evaluations are necessary to ensure comparability and standardization. This study aimed to compare the analytical performance of a Single Molecule Array (Simoa) and an ultrasensitive electrochemiluminescence (ECL) assay for quantifying neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in human serum. Baseline serum samples from 174 participants in the RIFUND trial were analyzed in parallel on both platforms. Concentrations of NfL and GFAP were compared using Spearman correlation, Bland-Altman analyses, reproducibility assessments, dilution linearity, and cross-platform recovery. All samples were quantifiable on both platforms. NfL concentrations correlated strongly between methods (Spearman correlation r = 0.88, p < 0.0001), whereas GFAP correlated moderately (r = 0.77, p < 0.0001). Inter- and intra-assay coefficients of variation were comparable between platforms for both analytes. The relationship between the two assays could be described with the following equations: NfL

Indexed as

BiomarkersElectrochemical TechniquesGlial Fibrillary Acidic ProteinLuminescent MeasurementsNeurofilament ProteinsNeurogliaSingle Molecule ImagingAdultFemaleHumansImmunoassayMaleMiddle AgedReproducibility of ResultsBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament ProteinsAnalytical platformsElectrochemiluminescence assayGlial fibrillary acidic proteinNeurofilament light chainNeuroglial biomarkersSingle-molecule array

Identifiers

PMID42380430

DOI10.1038/s41598-026-56794-x

PMCPMC13319466

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.